Skeletal muscle abnormalities in chronic heart failure patients: Relation to exercise capacity and therapeutic implications

Congestive Heart Failure

Volumn 9, Issue 3, 2003, Pages 148-154

  Nicoletti, Ilaria ^b   Cicoira, Mariantonietta ^a   Zanolla, Luisa ^b   Franceschini, Lorenzo ^b   Brighetti, Giovanna ^b   Pilati, Mara ^b   Zardini, Piero ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN;

DISEASE ASSOCIATION; EXERCISE TOLERANCE; HEART FAILURE; HEMODYNAMICS; HISTOLOGY; HUMAN; MUSCLE FUNCTION; MUSCLE MASS; MYOPATHY; OXYGEN CONSUMPTION; REVIEW; SYMPTOMATOLOGY; TRAINING; TREATMENT PLANNING; CONGESTIVE HEART FAILURE; EXERCISE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; ULTRASTRUCTURE;

EXERCISE; EXERCISE TOLERANCE; HEART FAILURE, CONGESTIVE; HUMANS; MUSCLE, SKELETAL; OXYGEN CONSUMPTION;

EID: 0041319195     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2002.01219.x     Document Type: Review

References (60)

1. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
2. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol. 1996;28:1092-1102.
3. Baker BJ, Wilen MM, Boyd CM, et al. Relation of right ventricular ejection fraction in chronic left ventricular failure. Am J Cardiol. 1984;54:596-599.
4. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47:33-39.
5. Weber KT, Wilson JR, Janicki J, et al. Exercise testing in the evaluation of patient with chronic heart failure. Am Rev Respir Dis. 1984;129:S60-S62.
6. Wilson JR, Rayos G, Yeoh TK, et al. Dissociation between peak exercise oxygen consumption and hemodynamic dysfunction in potential heart transplant candidates. J Am Coll Cardiol. 1995;26:429-435.
7. Wilson JR, Martin JL, Ferraro N, et al. Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure. Circulation. 1983;68:425-432.
8. Wilson JR, Martin JL, Ferraro N. Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: role of cardiac pump dysfunction as determined by the effect of dobutamine. Am J Cardiol. 1984;53:1308-1315.
9. Savin WM, Haskell WL., Schroeder JS, et al. Cardiopulmonary responses of cardiac transplant patients to graded, symptom limited exercise. Circulation. 1980;62:55-60.
10. Marzo KP, Herrmann HC, Mancini DM. Effect of balloon mitral valvuloplasty on exercise capacity, ventilation and skeletal muscle oxygenation. J Am Coll Cardiol. 1993;21:856-865.
11. Coats AJS, Clark AL, Piepoli M, et al. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994;72(S):S36-S69.
12. Broquist M, Arnquist H, Dahlstrom U, et al. Nutritional assessment and muscle energy metabolism in severe chronic heart failure-effects of long term dietary supplementation. Eur Heart J. 1994;15:1641-1650.
13. Vescovo G, Serafini F, Facchin L, et al. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart. 1996;76:337-343.
14. Piepoli M, Ponikowski P, Clark AL, et al. A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. Am Heart J. 1999;137:1050-1056.
15. Clark A, Coats AJS. The mechanisms underlying the increased ventilatory response to exercise in chronic stable heart failure. Eur Heart J. 1992;13:1698-1708.
16. Piepoli M, Clark AL, Ludman PF, et al. Muscle metaboreceptor in the hemodynamic, autonomic and ventilatory responses to exercise in men. Am J Physiol 1995;38(4):H1428-H1436.
17. Chua TP, Clark AL, Amadi AA, et al. Relation between chemosensitivity and ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1996;27:650-657.
18. Minotti JR, Pillay P, Oka R, et al. Skeletal muscle size: relationship to muscle function in heart failure. J Appl Physiol. 1993;75:373-381.
19. Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85:1364-1373.
20. Wilson JR, Fink L, Maris J, et al. Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance. Circulation. 1985;71:57-62.
21. Buller NP, Jones D, Poole-Wilson PA. Direct measurements of skeletal muscle function in patients with chronic heart failure. Br Heart J. 1991;65:20-24.
22. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30:1758-1764.
23. Dunnigam A, Staley NA, Smith SA, et al. Cardiac and skeletal muscle abnormalities in cardiomyopathy: comparison of patients with ventricular tachycardia or congestive heart failure. J Am Coll Cardiol 1987;10:608-618.
24. Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle abnormali ties in patients with chronic heart failure. Circulation. 1989;80:1338-1346.
25. Vescovo G, Volterrani M, Zennaro R, et al. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart. 2000;84:431-437.
26. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long term heart failure. Circulation. 1990;81:518-527.
27. Drexler H, Riede U, Munzel T, et al. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751-1759.
28. Lipkin D, Jones D, Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol. 1988;18:187-195.
29. Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance after losartan and enalapril in heart failure. Correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998;98:1742-1749.
30. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959-965.
31. Mancini DM, Ferraro N, Tuchler M, et al. Detection of abnormal muscle calf metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonance. Am J Cardiol. 1988;62:1234-1240.
32. Massie BM, Conway M, Yonge R, et al. 31-P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol. 1987;60:309-315.
33. Wiener DH, Fink LI, Maris J, et al. Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation. 1986;73:1127-1136.
34. Wilson JR, Martin JL, Schwartz D, et al. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation. 1984;69:1079-1087.
35. Wilson JR, Mancini DM, Dunkman WB. Exertional fatigue due to skeletal muscle dysfunction in patients with heart failure. Circulation. 1993;87:470-475.
36. Harrington H, Coats AJS. Skeletal muscle abnormalities and evidence for their role in symptom generation in chronic heart failure. Eur Heart J. 1997;18:1865-1872.
37. Vescovo G, Serafini F, Dalla Libera L, et al. Skeletal muscle myosin heavy chains in heart failure: correlation between magnitude of the isozyme shift, exercise capacity, and gas exchange measurements. Am Heart J. 1998;135:130-137.
38. Clark AL, Volterrani M, Swan JW, et al. The increased ventilatory response to exercise in chronic heart failure: relation to pulmonary pathology. Heart 1997;77:138-146.
39. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am failure Coll Cardiol. 1997;29:1585-1590.
40. Buller NP, Poole-Wilson PA. Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. Br Heart J. 1990;63:281-283.
41. Uren NG, Davies SW, Agnew JE, et al. Reduction of mismatch of global ventilation and perfusion on exercise is related to exercise capacity in chronic heart failure. Br Heart J. 1993;70:241-246.
42. Reindl I, Wemecke KD, Opitz C, et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J. 1998;136:778-785.
43. Franciosa JA, Leddy CL, Wilen M, et al. Relation between hemodynamic and ventilatory responses in determining exercise capacity in severe congestive heart failure. Am J Cardiol. 1984;53:127-134.
44. Clark AL, Sparrow JL, Coats AJS. Muscle fatigue and dyspnea in chronic heart failure: two sides of the same coin? Eur Heart J. 1995;16:49-52.
45. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-786.
46. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996;27:345-352.
47. Milani RV, Mehra MR, Reddy TK, et al. Ventilation/carbon dioxide production ratio in early exercise predicts poor functional capacity in congestive heart failure. Heart. 1996;76:393-396.
48. Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2001;37:2080-2085.
49. Osman AF, Mehra MR, Lavie CJ, et al. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. J Am Coll Cardiol. 2000;36:2126-2131.
50. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
51. Dalla Libera L, Ravara B, Angelini A, et al. Beneficial effects on skeletal muscle of the angiotensin II type I receptor blocker irbesartan in experimental heart failure. Circulation. 2001;103:2195-2200.
52. Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998;32:393-397.
53. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38:443-452.
54. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol. 1984;56:831-838.
55. Adamopoulos S, Coats AJS, Brunotte F, et al. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol. 1993;21:1101-1106.
56. Piepoli M, Clark AL, Volterrani M, et al. Contribution of muscle afferents to the hemodynamic, autonomic and ventilatory response to exercise in patients with chronic heart failure. Effects of physical training. Circulation. 1996;93:940-952.
57. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction: hemodynamic and metabolic effects. Circulation. 1988;78:506-515.
58. Coats AJS, Adamopoulos S, Meyer TE, et al. Effects of physical training in chronic heart failure. Lancet. 1990;335:63-66.
59. Coats AJS, Anker SD, Roecker EB, et al. Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: results of the COPERNICUS study. Circulation. 2001;104:II 437A.
60. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double blind, placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.